– Arvinas (ARVN) to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy. Evaluation of circulating kidney injury marker-1 (KIM-1) ...
Please provide your email address to receive an email when new articles are posted on . Clascoterone 5% topical solution targets the androgen receptor in the hair follicle without measurable systemic ...
This new technique for studying cell receptors could have sweeping implications for drug development
One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells. From beta blockers to antihistamines, these essential, life-saving medications ...
Estrogen and progesterone combined in OCs act in a synergistic manner in the gonadotropin axis. They decrease the secretion of hypophysial-luteinizing hormone and follicle-stimulating hormone by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback